• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
The Tokyo Cooperative Oncology Group - Developmental Therapeutics Review - Q4 2010 Product Image

The Tokyo Cooperative Oncology Group - Developmental Therapeutics Review - Q4 2010

  • ID: 1464359
  • December 2010
  • 38 pages
  • Global Markets Direct

The Tokyo Cooperative Oncology Group – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “The Tokyo Cooperative Oncology Group - Developmental Therapeutics Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- The Tokyo Cooperative Oncology Group - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of The Tokyo Cooperative Oncology Group human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
The Tokyo Cooperative Oncology Group Snapshot
Key Information
Key Facts
The Tokyo Cooperative Oncology Group – Research and Development Overview
Key Therapeutic Areas
The Tokyo Cooperative Oncology Group – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
The Tokyo Cooperative Oncology Group – Pipeline Products Glance
The Tokyo Cooperative Oncology Group – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
The Tokyo Cooperative Oncology Group Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
The Tokyo Cooperative Oncology Group – Drug Profiles
Irinotecan
Product Description
Mechanism of Action
R&D Progress
Irinotecan + Cisplatin
Product Description
Mechanism of Action
R&D Progress
TS-1 + Krestin
Product Description
Mechanism of Action
R&D Progress
Uracil-Tegafur + Cisplatin + Docetaxel + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Uracil-Tegafur + Cisplatin + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Paclitaxel + Bevacizumab
Product Description
Mechanism of Action
R&D Progress
Docetaxel + S-1
Product Description
Mechanism of Action
R&D Progress
Erlotinib
Product Description
Mechanism of Action
R&D Progress
Gefitinib + Carboplatin + Pemetrexed
Product Description
Mechanism of Action
R&D Progress
Taxol
Product Description
Mechanism of Action
R&D Progress
TS-1
Product Description
Mechanism of Action
R&D Progress
S-1 + Irinotecan + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
The Tokyo Cooperative Oncology Group – Pipeline Analysis
The Tokyo Cooperative Oncology Group – Pipeline Products by Therapeutic Class
The Tokyo Cooperative Oncology Group Pipeline Products By Target
The Tokyo Cooperative Oncology Group – Pipeline Products by Route of Administration
The Tokyo Cooperative Oncology Group – Pipeline Products by Molecule Type
The Tokyo Cooperative Oncology Group - Dormant Projects
The Tokyo Cooperative Oncology Group – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS